Neumora Therapeutics Q2 2024 GAAP EPS $(0.37), Inline
Portfolio Pulse from Benzinga Newsdesk
Neumora Therapeutics reported its Q2 2024 GAAP EPS at $(0.37), which is in line with expectations.
August 06, 2024 | 11:26 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Neumora Therapeutics reported its Q2 2024 GAAP EPS at $(0.37), which is in line with expectations.
The reported EPS of $(0.37) is in line with market expectations, suggesting no significant surprise. This is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100